학술논문
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Document Type
Review Paper
Author
Zhang, Tingting; Tian, Weiwei; Wei, Shuang; Lu, Xinyi; An, Jing; He, Shaolong; Zhao, Jie; Gao, Zhilin; Li, Li; Lian, Ke; Zhou, Qiang; Zhang, Huilai; Wang, Liang; Su, Liping; Kang, Huicong; Niu, Ting; Zhao, Ailin; Pan, Jing; Cai, Qingqing; Xu, Zhenshu; Chen, Wenming; Jing, Hongmei; Li, Peng; Zhao, Wanhong; Cao, Yang; Mi, Jianqing; Chen, Tao; Chen, Yuan; Zou, Ping; Lukacs-Kornek, Veronika; Kurts, Christian; Li, Jian; Liu, Xiansheng; Mei, Qi; Zhang, Yicheng; Wei, Jia
Source
Experimental Hematology & Oncology. 12(1)
Subject
Language
English
ISSN
2162-3619
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.